Resivant Medical Advances Cutiva PLUS in First Human Use
AKRON, Ohio, August 18, 2026 Resivant Medical announced the successful completion of the first patient cases using its Cutiva™...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
AKRON, Ohio, August 18, 2026 Resivant Medical announced the successful completion of the first patient cases using its Cutiva™...
VAN NUYS, Calif., August 18, 2026 Kandu, Inc. announced the publication of results from BCI-REHAB, the first randomized controlled...
GENEVA, Switzerland, July 9, 2026 MindMaze Therapeutics Holding SA has announced its support for a University of Pittsburgh clinical...
VALENCIA, Calif., June 29, 2026 Bioness Medical, Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
